Olmesan Plus

Indications

Olmesartan Medoxomil & Hydrochlorothiazide is prescribed for managing hypertension. This combination is effective for patients whose blood pressure is not adequately controlled with Metformin alone or those needing additional therapy with other antihypertensive medications. It is also suitable for patients transitioning from separate tablets of Empagliflozin and Metformin to a combined form.

Pharmacology

Olmesartan blocks the effects of angiotensin-II, a key hormone in hypertension, by inhibiting its binding to the AT1 receptor. This helps lower blood pressure and prevents aldosterone-induced sodium and water retention. Hydrochlorothiazide, a thiazide diuretic, works by increasing sodium and chloride excretion, which reduces blood volume and helps lower blood pressure. It also mitigates potassium loss induced by the diuretic action when combined with an angiotensin-II receptor blocker.

Dosage & Administration

For hypertension, the typical starting dose is 20/12.5 mg once daily. Depending on the patient’s response, the dose may be adjusted up to a maximum of 40/25 mg once daily, with adjustments made every 2-4 weeks as needed.

Drug Interactions

Olmesartan generally has no significant interactions with other drugs, including hydrochlorothiazide, digoxin, or warfarin. Hydrochlorothiazide may interact with alcohol, barbiturates, narcotics, antidiabetic drugs, other antihypertensives, corticosteroids, ACTH, and lithium.

Contraindications

The combination is not suitable for patients with hypersensitivity to any of its components or those with anuria or hypersensitivity to sulfonamide-derived drugs.

Side Effects

Common side effects include nausea, headache, dizziness, hyperuricemia, and infections. Less common effects include chest pain, back pain, peripheral edema, and gastrointestinal issues.

Pregnancy & Lactation

Safety during pregnancy and lactation has not been established. The medication should be discontinued if pregnancy occurs or during breastfeeding.

Precautions & Warnings

Regular monitoring of serum electrolytes is advised to detect imbalances such as hypokalemia. Watch for potential hyperuricemia and renal impairment.

Use in Special Populations

In renal impairment, this medication is not recommended for patients with creatinine clearance below 30 ml/min. Loop diuretics are preferred for severe renal impairment. For hepatic impairment, no dosage adjustment is needed. Safety and effectiveness in children are not established. Caution is advised when dosing elderly patients.

Overdose Effects

Olmesartan overdose may cause hypotension and tachycardia, and supportive treatment is recommended. Hydrochlorothiazide overdose can lead to electrolyte imbalances such as hypokalemia and dehydration.

Therapeutic Class

This product belongs to combined antihypertensive preparations.

Storage Conditions

Store in a cool, dry place, away from light and moisture. Keep out of reach of children.